[1. S. C. Sweetman (Ed.), Martindale: The Complete Drug Reference, 36th ed., Pharmaceutical Press, London 2009, p. 80.]Search in Google Scholar
[2. M. Batt, Non-coeliac flat jejunal mucosa, Gut 30 (1989) 67-68.10.1136/gut.30.Spec_No.67]Search in Google Scholar
[3. T. Hamaguchi, D. Shinkuma, Y. Yamanaka and N. Mizuno, Bioavailability of mefenamic acid: influence of food and water intake, J. Pharm. Sci. 75 (1986) 891-893.]Search in Google Scholar
[4. J. L. Wallace, Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World J. Gastroenterol. 19 (2013) 1861-1876; DOI: 10.3748/wjg.v19.i12.1861.10.3748/wjg.v19.i12.1861361310223569332]Search in Google Scholar
[5. D. V. Derle, M. Bele and N. Kasliwal, In vitro and in vivo evaluation of mefenamic acid and its complexes with b-cyclodextrin and HP-b-cyclodextrin, Asian J. Pharm. 2 (2008) 30-34; DOI: 10. 4103/0973-8398.41562.10.4103/0973-8398.41562]Search in Google Scholar
[6. G. L. Amidon, H. Lennernas, V. P. Shah and J. R. Crison, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res. 12 (1995) 413-420.]Search in Google Scholar
[7. D. Mudit, Y. Bhardwaj, P. K. Keshavarao and P. Selvam, Enhancing solubility and dissolution of mefenamic acid by freeze drying using b-cyclodextrin, Int. Res. J. Pharm. 2 (2011) 146-150; DOI: http://dx.doi.org/10.1590/S1984-82502011000400011.10.1590/S1984-82502011000400011]Search in Google Scholar
[8. U. Domanska, A. Pelczara and A. Pobudowska, Effect of 2-hydroxypropyl-b-cyclodextrin on solubility of sparingly soluble drug derivatives of anthranilic acid, Int. J. Mol. Sci. 12 (2011) 2383-2394; DOI: 10.3390/ijms12042383.10.3390/ijms12042383312712321731447]Search in Google Scholar
[9. I. Fülöp, Á. Gyéresi and Ș. Hobai, Characterisation of the interaction between fenamates and hydroxy- propyl-b-cyclodextrin, Bull. Med. Sci. 83 (2010) 58-62.]Search in Google Scholar
[10. K. R. Rao, M. V. Nagabhushanam and K. P. Chowdary, In vitro dissolution studies on solid dispersions of mefenamic acid, Indian J. Pharm. Sci. 73 (2011) 243-247; DOI: 10.4103/0250-474X.91575.10.4103/0250-474X.91575]Search in Google Scholar
[11. G. Owusu-Ababio, N. K. Ebube, R. Reams and M. Habib, Comparative dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems and tablets, Pharm. Dev. Technol. 3 (1998) 405-412; DOI: 10.3109/10837459809009868.10.3109/108374598090098689742561]Search in Google Scholar
[12. A. Dahan A and J. M. Miller, The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs, AAPS J. 14 (2012) 244-251; DOI: 10.1208/ s12248-012-9337-6. 10.1208/s12248-012-9337-6332616022391790]Search in Google Scholar
[13. A. Beig, R. Agbaria and A. Dahan, Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations, Plos One 8 (2013) e68237; DOI: 10.1371/journal.pone.0068237.10.1371/journal.pone.0068237371297023874557]Search in Google Scholar
[14. G. E. Amidon, W. I. Higuchi and N. F. Ho, Theoretical and experimental studies of transport of micelle-solubilized solutes, J. Pharm. Sci. 71 (1982) 77-84.10.1002/jps.26007101207057387]Search in Google Scholar
[15. J. M. Miller, A. Beig, R. A. Carr, G. K. Webster and A. Dahan, The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations, Mol. Pharm. 9 (2012) 581-590; DOI: 10.1021/mp200460u.10.1021/mp200460u]Search in Google Scholar
[16. A. Beiq, J. M. Miller and A. Dahan, Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption, Eur. J. Pharm. Biopharm. 81 (2012) 386-391; DOI: 10.1016/j.ejpb.2012.02.012.10.1016/j.ejpb.2012.02.012]Search in Google Scholar
[17. L. Kiss, E. Hellinger, A. M. Pilbat, A. Kittel, Z. Török, A. Füredi, G. Szakács, S. Veszelka, P. Sipos, B. Ózsvári, L. G. Puskás, M. Vastag, P. Szabó-Révész and M. A. Deli, Sucrose esters increase drug penetration, but do not inhibit P-glycoprotein in Caco-2 intestinal epithelial cells, J. Pharm. Sci. 103 (2014) 3107-3119; DOI: 10.1002/jps.24085.10.1002/jps.24085]Search in Google Scholar
[18. A. Szűts and P. Szabó-Révész, Sucrose esters as natural surfactants in drug delivery systems - a mini-review, Int. J. Pharm. 433 (2012) 1-9; DOI: 10.1016/j.ijpharm.2012.04.076.10.1016/j.ijpharm.2012.04.076]Search in Google Scholar
[19. T. Hladon, J. Pawlaczyk and B. Szafran, Stability of mefenamic acid in the inclusion complex with b-cyclodextrin in the solid phase, J. Incl. Phenom. Macrocycl. Chem. 35 (1999) 497-506; DOI: 10.1023/ A:1008048612736.10.1023/A:1008048612736]Search in Google Scholar
[20. Ryoto Sugar Ester Technical Information, Ryoto Sugar Ester (Food grade)/ Surfhope™ SE Pharma, Mitsubishi-Kagaku Foods Corporation; http://www.mfc.co.jp/english; last access date May 25, 2015.]Search in Google Scholar
[21. A. Szűts, E. Pallagi, G. Regdon, Jr., Z. Aigner and P. Szabó-Révész, Study of thermal behaviour of sugar esters, Int. J. Pharm. 336 (2007) 199-207; DOI: 10.1016/j.ijpharm.2006.11.053.10.1016/j.ijpharm.2006.11.053]Search in Google Scholar
[22. A. Szűts, Zs. Makai, R. Rajkó and P. Szabó-Révész, Study of the effects of drugs on the structures of sucrose esters and the effects of solid-state interactions on drug release, J. Pharm. Biomed. Anal. 48 (2008) 1136-1142; DOI: 10.1016/j.jpba.2008.08.028.10.1016/j.jpba.2008.08.028]Search in Google Scholar
[23. European Pharmacopoeia 8th ed., Council of Europe, Strasbourg 2013, pp. 288-295.]Search in Google Scholar
[24. Y. Zhang, M. Huo, J. Zhou, A. Zou, W. Li, C. Yao and S. Xie, DDSolver: an add-in program for modeling and comparison of drug dissolution profiles, AAPS J. 12 (2010) 263-271; DOI: 10.1208/ s12248-010-9185-1.]Search in Google Scholar
[25. P. Costa and J. M. Sousa Lobo, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133; DOI: 10.1016/S0928-0987(01)00095-1.10.1016/S0928-0987(01)00095-1]Search in Google Scholar
[26. I. Fülöp, Á. Gyéresi, M. A. Deli, L. Kiss, M. D. Croitoru, P. Szabó-Révész and Z. Aigner, Ternary solid dispersions of oxicams: Dissolution and permeability study, Farmacia 63 (2015) 286-295.]Search in Google Scholar
[27. M. Dixit, A. Kini and P. K. Kulkarni, Enhancing the dissolution of polymorphs I and II of mefenamic acid by spray drying, Turk. J. Pharm. Sci. 9 (2012) 13-26.]Search in Google Scholar
[28. S. Romero, B. Escalera and P. Bustamante, Solubility behavior of polymorphs I and II of mefenamic acid in solvent mixtures, Int. J. Pharm. 178 (1999) 193-202.10.1016/S0378-5173(98)00375-5]Search in Google Scholar
[29. S. G. Vijaya Kumar and D. N. Mishra, Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG 6000, Yakugaku Zasshi (J. Pharm. Sci. Japan) 126 (2006) 657-664.10.1248/yakushi.126.65716880724]Search in Google Scholar
[30. H. Lokhandwala, A. Deshpande and S. Deshpande, Kinetic modelling and dissolution profiles comparison: an overview, Int. J. Pharm. Biol. Sci. 4 (2013) 728-737. ]Search in Google Scholar